MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

BioMarin Pharmaceutical Inc

Fechado

SetorSaúde

68.39 0.66

Visão Geral

Variação de preço das ações

24h

Atual

Mín

67.38

Máximo

68.39

Indicadores-chave

By Trading Economics

Rendimento

19M

125M

Vendas

1.6M

747M

P/E

Médio do Setor

31.986

63.778

EPS

0.92

Margem de lucro

16.719

Funcionários

3,040

EBITDA

39M

195M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+46.29% upside

Dividendos

By Dow Jones

Próximos Ganhos

23 de abr. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.6B

14B

Abertura anterior

67.73

Fecho anterior

68.39

Sentimento de Notícias

By Acuity

11%

89%

10 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

BioMarin Pharmaceutical Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de jun. de 2024, 17:41 UTC

Grandes Movimentos do Mercado

Texas Pacific Land, Altair Engineering Hit 52-Week Highs on S&P MidCap 400 Inclusion

21 de ago. de 2024, 11:30 UTC

Principais Notícias

S&P 500 Futures Up In Premarket Trading; Target, Keysight Technologies Lead

Comparação entre Pares

Variação de preço

BioMarin Pharmaceutical Inc Previsão

Preço-alvo

By TipRanks

46.29% parte superior

Previsão para 12 meses

Média 99.39 USD  46.29%

Máximo 127 USD

Mínimo 70 USD

Com base em 24 analistas de Wall Street que oferecem metas de preço de 12 meses para BioMarin Pharmaceutical Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

24 ratings

19

Comprar

5

Manter

0

Vender

Pontuação Técnica

By Trading Central

N/A / 70.83Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

10 / 386 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.